Commentary: Dissecting the US FDA's Coartem approval
This article was originally published in Scrip
Executive Summary
With US approval of its antimalarial Coartem (artemether plus lumefantrine) earlier this month, Novartis became the first pharmaceutical company to win a coveted priority review voucher from the FDA.